Melphalan Koanaa

Melphalan, the active ingredient in Melphalan Koanaa, is an alkylating agent presented as an injectable formulation for intra‑arterial or intravenous use. It is employed in chemotherapy protocols for multiple myeloma, ovarian cancer, melanoma and other solid tumours. GNH USA supplies Melphalan Koanaa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan Koanaa is an alkylating chemotherapy agent indicated for several malignant disease categories. - Multiple Myeloma: used as part of combination regimens to eradicate malignant plasma cells. - Ovarian Cancer: incorporated into treatment cycles to reduce tumour burden. - Melanoma: administered in advanced stages to inhibit proliferating melanoma cells. - Other Solid Tumours: applied where standard protocols include an alkylating agent for tumour control.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Bone‑marrow suppression (anemia, neutropenia, thrombocytopenia) - Alopecia (hair loss) - Fatigue - Mucositis (mouth sores) - Diarrhea

Serious or Rare Side Effects: - Secondary malignancies (e.g., acute leukemia) - Severe infections due to immunosuppression - Pulmonary toxicity (interstitial pneumonitis) - Renal impairment or failure - Hemorrhagic complications - Cardiac toxicity (arrhythmias, myocarditis)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity. - Renal function: assess baseline creatinine and adjust if impaired. - Hematologic monitoring: perform regular complete blood counts to detect marrow suppression. - Pregnancy: avoid use unless potential benefit justifies risk; discuss contraception. - Drug interactions: review concomitant myelosuppressive or nephrotoxic agents. - Administration technique: ensure aseptic preparation and infusion under medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Other myelosuppressive agents: may cause profound bone‑marrow toxicity. - High‑dose radiation therapy: increased risk of severe tissue damage.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk. - Nephrotoxic drugs (e.g., aminoglycosides): may exacerbate renal injury. - CYP450 inhibitors (e.g., azole antifungals): potential increase in melphalan exposure.